OPKO’s current molecular diagnostics programs include:
Biomarkers for Alzheimer’s Disease
Research published in the January 2011 edition of the journal Cell identified three peptoid probes able to selectively identify autoantibody levels that are dramatically higher in Alzheimer’s patients as compared to non-Alzheimer’s patient controls.
OPKO has also entered into a nonexclusive license agreement with Bristol Myers Squibb (BMS) to further develop an Alzheimer’s disease diagnostic test.
We expect the BMS diagnostic test to be useful in:
- Stratifying patients for ongoing clinical trials of potential Alzheimer’s drugs
- Confirming Alzheimer’s diagnosis in a clinical setting
- Tracking the progression of the disease
- Tracking the effectiveness of an Alzheimer’s therapeutic in a clinical trial
Commercial Alzheimer’s Diagnostics:
OPKO expects to market an Alzheimer’s disease test for use at the patient point-of-care.
In 2012, OPKO licensed intellectual property to Laboratory Corporation of America (LabCorp) for the development and commercialization of an Alzheimer’s diagnostic test in laboratory-developed-test format. LabCorp holds exclusive commercial rights to product marketing in the United States and the United Arab Emirates.
Thomas Kodadek, a professor at the Scripps Research Institute in Florida and Director of Chemistry and Molecular Biology at OPKO, received a $4.2 million grant from the NIH National Institute of Diabetes and Digestive and Kidney Disease. OPKO and Scripps are currently conducting collaborative studies on the early autoimmune reactions that underlie type-1 diabetes.